Efficacy & Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment

NCT ID: NCT02379468

Last Updated: 2015-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2014-10-31

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Pedyphar® ointment in the healing of foot ulceration in diabetic patients.

Conditions

Diabetic Foot Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pedyphar

Ointment

Group Type: EXPERIMENTAL

Pedyphar Ointment

Intervention Type: DRUG

Panthenol

Ointment

Group Type: ACTIVE_COMPARATOR

Panthenol

Intervention Type: DRUG

Ointment

Interventions

Pedyphar Ointment

Intervention Type: DRUG

Panthenol

Ointment

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent signed and dated by study subject.

2. Male or Female patients.

3. Age is ≥18 years old and ≤ 70 years old.

4. Clinical diagnosis of Diabetes Mellitus Type I or II with diabetic foot ulcer. A past history of Diabetes Mellitus and/or the use of anti-diabetic medications for the treatment of Diabetes Mellitus with diabetic foot ulcer are sufficient.

5. Presence of 1 or more DFU, less than 15 cm in its biggest diameter, with a Texas University grade ≤ 2 and ≤ grade 2 according to the Wagner Grading system.

6. Diabetic foot ulcer has been present for at least 4 weeks and no more than 2 years prior to screening.

7. If there is Diabetic Foot Ulcer Infection, It must be:

1. Mild ( Presence of ≥ 2 manifestations of inflammation (purulence, or erythema, pain, tenderness, warmth, or indurations),any cellulitis/erythema extending ≤ 2 cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness).

Or:

2. Moderate Infection (as above) in a patient who is systemically well and metabolically stable but which has ≥1 of the following characteristics: cellulitis extending >2 cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle, tendon, joint or bone.

8. If subject is female and of childbearing potential, she agrees to use a medically acceptable physical barrier method contraceptive during the treatment phase.

9. Be willing and able to participate in the study as an outpatient, make the required visits to the study center during the treatment periods, and comply with study requirements.

10. Receiving medical care for diabetes.

Exclusion Criteria

1. DFU with a Texas score >2 and > grade 2 according to the Wagner Grading system.

2. Severe Infected DFU with clinical or para-clinical findings suggesting osteomyelitis (Infection in a patient with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, or azotemia)

3. Clinically defined and documented severe arterial disease.

4. History of radiation therapy to the ulcer site.

5. If the study subject has Foot Ulcer of no diabetic pathophysiology.

6. Receiving corticosteroids or immune suppressive agents.

7. History of immune-vascular disease.

8. Known hypersensitivity to any component of Pedyphar® or Panthenol.

9. Patients undergoing hemodialysis.

10. Insufficient blood supply to Lower Limb (ankle-brachial index < 0.9).

11. Clinical findings suggesting complicated venous insufficiency of LL. Edema [Hyper pigmentation, Venous dermatitis, Chronic cellulitis, Cutaneous infarction (atrophie blanche), Ulceration]

12. Received treatment with any other investigational drug or device within the last 30 days

13. Unable to comply with the procedures described in the protocol

14. History of moderate to severe ischemic heart disease or any history of congestive heart failure, or has had a myocardial infarction within the previous 6 months.

15. Patients with a history of major hematological, renal or hepatic abnormalities.

16. Mentally or neurologically disabled patients that are considered not fit to approve their participation in the study.

17. Refusal to give informed consent.

18. Pregnant or Breastfeeding subjects.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

European Egyptian Pharmaceutical Industries

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Samir H. Asaad, Prof.

Role: PRINCIPAL_INVESTIGATOR

Alexandria University

Locations

Alexandria University

Alexandria, Alexandria Governorate, Egypt

Tanta University

Tanta, Please Select, Egypt

Ain Shames University

Cairo, , Egypt

Suez Canal University

Suez, , Egypt

Countries

Egypt

Other Identifiers

EEPI_ PED_001

Identifier Type: -

Identifier Source: org_study_id